AB044. SOH23ABS_117. Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor positive breast cancer: a systematic review and network meta-analysis

Matthew P. Davey,Eoin F. Cleere, J. M. O’Donnell,Sara Gasior,Aoife Lowery, Michael J. Kerin

Mesentery and peritoneum（2023）

Cited 0|Views1

No score

Abstract

Background: The OncotypeDX© 21-gene Recurrence Score (RS) estimates the risk of distant-disease recurrence in early-stage estrogen receptor positive, human epidermal growth factor receptor-2 negative (ER+/HER2−) breast cancer. Using RS to estimate risk of locoregional recurrence (LRR) is less conclusive. We aimed to perform network meta-analysis (NMA) evaluating the RS in estimating LRR in ER+/HER2− breast cancer.

Translated text

Key words

estrogen receptor,positive breast cancer,breast cancer,meta-analysis

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined